NextCure, Inc. (NASDAQ:NXTC) Receives Consensus Recommendation of “Hold” from Analysts

NextCure, Inc. (NASDAQ:NXTC) has earned a consensus rating of “Hold” from the four analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $16.50.

NXTC has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of NextCure in a research note on Monday, April 27th. Zacks Research raised NextCure from a “strong sell” rating to a “hold” rating in a report on Thursday, June 11th.

NextCure Stock Performance

Shares of NASDAQ:NXTC opened at $1.88 on Friday. NextCure has a 52 week low of $1.55 and a 52 week high of $15.74. The company’s fifty day moving average is $5.69 and its 200-day moving average is $9.87. The company has a market capitalization of $6.79 million, a PE ratio of -0.11 and a beta of 1.42.

NextCure (NASDAQ:NXTC) last announced its earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.10) by $0.23. On average, analysts forecast that NextCure will post -7.9 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Marshall Wace LLP acquired a new stake in shares of NextCure during the 4th quarter worth approximately $160,000. Millennium Management LLC acquired a new position in NextCure in the fourth quarter valued at approximately $185,000. Geode Capital Management LLC boosted its stake in NextCure by 18.6% in the fourth quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock valued at $329,000 after acquiring an additional 3,636 shares during the last quarter. Renaissance Technologies LLC boosted its stake in NextCure by 18.7% in the fourth quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after acquiring an additional 5,300 shares during the last quarter. Finally, Boothbay Fund Management LLC acquired a new stake in NextCure during the 4th quarter worth $988,000. 42.65% of the stock is owned by institutional investors.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.